Moneycontrol PRO
HomeNewsBusinessDr Reddy's Laboratories launches generic hemophilia injection in US

Dr Reddy's Laboratories launches generic hemophilia injection in US

According to IQVIA health data, the desmopressin acetate injection USP brand and generic market had US sales of approximately $20.9 million MAT for the 12 months ended March 2020, it added.

May 06, 2020 / 15:29 IST

Dr Reddy's Laboratories on Wednesday said it has launched generic Desmopressin Acetate injection indicated for treatment of hemophilia, in the US. The company has launched Desmopressin Acetate injection USP, 4 mcg/mL single-dose ampules in the US market, Dr Reddy's Laboratories said in a filing to the BSE.

According to IQVIA health data, the desmopressin acetate injection USP brand and generic market had US sales of approximately $20.9 million MAT for the 12 months ended March 2020, it added.

"The launch of desmopressin injection demonstrates a strong, growing collaboration with SunGen Pharma. We look forward to future opportunities with this company," Dr Reddy's Laboratories North America Generics CEO Marc Kikuchi said.

The product is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5 per cent.

"We are pleased to be working with Dr Reddy's for this launch. The launch of desmopressin demonstrates our strong development capabilities. We look forward to collaborating further to bring specialty pharmaceutical drugs to the markets around the world," SunGen Co-CEO Isaac Liu said.

Shares of Dr Reddy's Laboratories were trading at Rs 3,827.90 per scrip on the BSE, down 0.19 percent from the previous close.

PTI
first published: May 6, 2020 03:15 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347